Biosimilar ranibizumab (BS1) – early experience from Japan (BRIJ study)
Author:
Ueda-Consolvo Tomoko, Ishida Masaaki, Nakamura Tomoko, Yanagisawa Shuichiro, Tsuboi Kotaro, Wakabayashi TakuORCID, Hayashi Atsushi, Sharma AshishORCID, Kuppermann Baruch D., Loewenstein Anat, Bandello Francesco, Regillo Carl D., Nicholson Luke, Vazquez-Alfageme Clara, Kumar Nilesh, Parachuri Nikulaa, Sheth Jay, Ayachit Seemantini, Mishra Chitaranjan, Chakraborty Debdulal, Banker Alay, Rezaei Kourous A., Khanani Arshad M., Kaiser Peter K., Tadayoni Ramin, Holz Frank G., Sivaprasad Sobha, Sarraf David, Querques Giuseppe, Özdek Şengül, Laurent Kodjikian, Bilgic Alper, Lanzetta Paolo, Baumal Caroline, Holekemp Nancy, Sakamoto Taiji, Tufail Adnan, Yannuzzi Nicolas, Corradetti Giulia, Hilely Assaf, Boyer David, Rachitskaya Aleksandra, Peto Tunde, Wintergerst Maximilian W. M., Sarao Valentina, Parolini Barbara, Mruthyunjaya Prithvi, Nguyen Quan Dong, DO Diana V., Keane Pearse A., Hassan Tarek, Sridhar Jayanth, Eichenbaum David, Grewal Dilraj S., March Francesc, Splitzer Martin, Zinkernage Martin S.,
Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Sharma A, Kondo M, Iwahashi C, Parachuri N, Kumar N, Bandello F, et al. Approved biosimilar ranibizumab-a global update. Eye (Lond). 2023;37:200–2. 2. Sharma A, Holz FG, Regillo CD, Freund KB, Sarraf D, Khanani AM, et al. International Retina Biosimilar Study Group (Inter BIOS Group). Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey). Expert Opin Biol Ther. 2023;23:851–9. 3. Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real-Life clinical effectiveness of Razumab® (the world’s first biosimilar of ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT study. Ophthalmologica. 2019;241:24–31. 4. Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real life clinical effectiveness of Razumab® (world’s first biosimilar ranibizumab) in wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: A retrospective pooled analysis. Int J Oph thalmol Eye Res. 2018;6:368–73. 5. ASRS. Efficacy and safety of biosimilars ranibizumab-nuna and ranibizumab eqrn in clinical use. (2023). https://www.ophthalmologytimes.com/view/asrs-2023-efficacy-and-safety-of-biosimilars-ranibizumab-nuna-and-ranibizumab-eqrn-in-clinical-use.
|
|